Advaxis (ADXS) Hits New 52-Week Low at $1.88

Advaxis, Inc. (NASDAQ:ADXS) shares reached a new 52-week low on Thursday . The company traded as low as $1.88 and last traded at $2.51, with a volume of 500100 shares trading hands. The stock had previously closed at $2.51.

A number of research analysts have weighed in on the stock. ValuEngine upgraded shares of Advaxis from a “strong sell” rating to a “sell” rating in a research note on Friday, February 2nd. Cantor Fitzgerald set a $19.00 target price on shares of Advaxis and gave the company a “buy” rating in a research note on Friday, December 22nd. Finally, HC Wainwright reiterated a “buy” rating and issued a $23.00 target price on shares of Advaxis in a research note on Wednesday, November 8th.

The stock has a market capitalization of $78.52, a P/E ratio of -0.82 and a beta of 0.70.

Advaxis (NASDAQ:ADXS) last announced its quarterly earnings results on Wednesday, December 20th. The biotechnology company reported ($0.57) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.55) by ($0.02). The business had revenue of $1.76 million for the quarter, compared to analysts’ expectations of $3.05 million. Advaxis had a negative net margin of 776.63% and a negative return on equity of 114.00%. research analysts forecast that Advaxis, Inc. will post -2.36 earnings per share for the current year.

Hedge funds have recently made changes to their positions in the stock. Voya Investment Management LLC lifted its stake in shares of Advaxis by 20.3% during the 2nd quarter. Voya Investment Management LLC now owns 17,612 shares of the biotechnology company’s stock valued at $114,000 after buying an additional 2,975 shares in the last quarter. PNC Financial Services Group Inc. lifted its stake in shares of Advaxis by 18.2% during the 2nd quarter. PNC Financial Services Group Inc. now owns 26,000 shares of the biotechnology company’s stock valued at $168,000 after buying an additional 4,000 shares in the last quarter. The Manufacturers Life Insurance Company lifted its stake in shares of Advaxis by 10.4% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 31,431 shares of the biotechnology company’s stock valued at $204,000 after buying an additional 2,969 shares in the last quarter. Stonebridge Capital Management Inc. lifted its stake in shares of Advaxis by 88.7% during the 3rd quarter. Stonebridge Capital Management Inc. now owns 42,650 shares of the biotechnology company’s stock valued at $179,000 after buying an additional 20,045 shares in the last quarter. Finally, Wells Fargo & Company MN lifted its stake in shares of Advaxis by 2.6% during the 2nd quarter. Wells Fargo & Company MN now owns 44,813 shares of the biotechnology company’s stock valued at $290,000 after buying an additional 1,144 shares in the last quarter. Institutional investors own 37.39% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This piece of content was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece of content on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at https://www.dispatchtribunal.com/2018/02/24/advaxis-adxs-hits-new-52-week-low-at-1-88.html.

Advaxis Company Profile

Advaxis, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins.

Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply